Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna (OTCQX:MDNAF) reported dosing the first patient in NEO-CYT, an investigator-initiated neoadjuvant Phase 1b trial of MDNA11 in high-risk, surgically resectable Stage III cutaneous melanoma in Italy.
The study evaluates MDNA11 plus nivolumab, with or without ipilimumab, targeting major pathologic response before curative-intent surgery.
Medicenna (MDNAF) announced a poster presentation on the randomized neoadjuvant NEO-CYT Phase 1b trial testing MDNA11 with nivolumab ± ipilimumab in high‑risk, surgically resectable Stage III melanoma at ASCO 2026 in Chicago, May 29–June 3.
Presenter: Paolo Antonio Ascierto, MD; Poster #: 488a; Abstract: TPS9612; Session: Melanoma/Skin Cancers; Date/time: May 31, 9:00 AM–12:00 PM CDT. Trial sponsor: Fondazione Melanoma Onlus. EudraCT ID: 2024-519010-31-00.
Medicenna (OTCQX: MDNAF) presented preclinical data for MDNA113, a tumor-anchored, conditionally activated anti-PD-1 x IL-2 bifunctional Superkine, at AACR 2026. MDNA113 showed >10,000-fold IL-2 attenuation when masked, tumor residence ≥3 days, dual activation mechanisms, and tolerability up to 50 mg/kg in non-human primates.
The molecule demonstrated tumor-selective activation, CD8+ T-cell expansion, pharmacokinetics consistent with approved anti-PD-1 antibodies, and a therapeutic window reportedly >30-fold wider than a comparator, supporting an IND submission expected in H2 2026.
Medicenna (OTCQX: MDNAF) said President and CEO Dr. Fahar Merchant will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21, 2026 at 3:00 p.m. ET.
The company will provide a corporate update and share latest MDNA113 preclinical data from AACR 2026. A live webcast and a replay (available for 90 days) are accessible via the company webcast link and the Investor Relations site.
Medicenna (TSX: MDNA, OTCQX: MDNAF) named Dr. Nageatte Ibrahim as Chief Medical Officer effective April 9, 2026. Dr. Ibrahim will serve in a fractional capacity and brings >20 years of oncology drug‑development experience, including roles at Merck, GSK, Innovent, and academic appointments at Harvard and Penn.
Her experience includes leadership on pembrolizumab programs and oversight of global registration studies, supporting Medicenna’s IL‑2 superagonist and anti‑PD1‑IL‑2 bifunctional programs.
Medicenna (OTCQX: MDNAF) will present updated preclinical data for MDNA113, a masked, tumor‑anchored anti‑PD‑1‑IL‑2 bifunctional Superkine, at AACR Annual Meeting 2026 on April 21 (Poster Section 9, Board 13).
The program is advancing toward an IND submission in H2 2026 and the poster highlights in vivo tumor selectivity, localization, potency and non‑human primate immunodynamic and safety data supporting a differentiated tolerability profile.
Medicenna (OTCQX: MDNAF, TSX: MDNA) announced participation in multiple industry conferences between Feb 19 and Mar 25, 2026 to present clinical program updates and meet investors.
Key events: Feb 19 Boston (Glioblastoma Summit) — presentation by Dr. Fahar Merchant on bizaxofusp; Mar 2-3 Miami (BIO Investment); Mar 22-24 Dana Point (ROTH) webcast available; Mar 23-25 Lisbon (BIO-Europe Spring).
Medicenna (OTCQX: MDNAF) reported Q3 fiscal 2026 results and a corporate update on Feb 13, 2026. Key clinical wins include MDNA11 ORR 36% (mono) and 43% (combo) in expansion cohorts and bizaxofusp mOS 13.6 months in IDHWT high-dose rGBM. Cash was $10.6M, providing runway into Q3 2026.
MDNA113 advanced through IND-enabling studies with favorable NHP safety at 30 mg/kg; multiple clinical readouts and an IND filing are planned in H2 2026.
Medicenna (TSX: MDNA, OTCQB: MDNAF) announced board changes effective Feb 12, 2026: Richard Sutin and Angelos Georgakis were appointed to the board, following the retirement of Karen Dawes, who served since 2019 and chaired the Compensation Committee. The company highlighted their capital markets and biotech advisory experience.
The CEO said the new directors will support strategic growth and that Dawes will continue as a consultant.
Medicenna (OTCQX: MDNAF) provided a 2026 outlook and program updates focused on MDNA11, MDNA113 and bizaxofusp. ABILITY-1 has enrolled >110 safety-evaluable patients (102 efficacy-evaluable) across 29 cancer types; biologically effective dose range was set at 60–120 µg/kg with no dose-limiting toxicities. Key efficacy: monotherapy expansion cohorts (n=21) showed 50% ORR in 2L/3L patients and 42% ORR post-ICI failure; overall monotherapy (n=55) ORR was 19% (2L/3L) and 24% (post-ICI). MDNA113 NHP data tolerable to 30 mg/kg; IND planned H2 2026. Cash runway into Q3 2026.